Retinitis Pigmentosa Clinical Trial
Official title:
Stress and Vision Fluctuations in Retinitis Pigmentosa
Retinitis pigmentosa (RP) patients experience a slowly progressive, unpredictable loss of vision which eventually leads to bare or no light perception, posing a continuous threat to patients' independence. Negative psychological states such as distress, sleepiness, anxiety and depression are common in RP patients due to the nature of this chronic, disabling disease. Psychophysical vision measures are more variable in legally blind RP subjects than in normally sighted individuals, and RP patients indicate that variations in vision are often related to stress. The primary goal of this research is to examine the vision fluctuations within and between days among RP patients using vision tests self-administered by patients through their home computers, and determine associations with factors such as perceived stress, mood states, sleepiness, or light exposure. The administration of questionnaires will allow us to gain some insight into which underlying psychological factors impact certain vision measures, allowing the design of future interventional research to attempt to reduce such factors. The aims of many future treatment clinical trials for RP will be to improve vision and/or reduce the rate of vision loss; thus the sources that lead to increased variability of vision need to be identified and alleviated to enable precise evaluation of interventions and improve patients' quality of life.
An initial study visit for enrollment will take place at the Johns Hopkins Wilmer Eye
Institute's Lions Vision Center. The investigators will enroll 50 RP subjects with vision
better than hand motions or bare light perception, who are able to complete PC-based vision
tests. Written informed consent for study participation will be obtained at the first study
visit.
At home PC-based vision tests will be performed bi-weekly, for 2 months (i.e. 16 measures)
to capture the full range of variability. Binocular visual acuity (VA), contrast sensitivity
(CS) and visual field (VF) tests will be self-administered by the RP subjects, and will take
~10 minutes. Three brief questionnaires will be administered by PC after each vision test
session: 1) Perceived Stress Scale (PSS); 2) Stanford Sleepiness Scale (SSS); and 3)
Positive and Negative Affect Schedules (PANAS). Lab-based vision tests will take place at
the time of enrollment, and will include: (1) distance best-corrected VA with the ETDRS
charts, (2) Pelli-Robson letter CS, (3) Goldmann VF with V/4e and III/4e isopters, and (4)
Humphrey 10-2 or 30-2 VF FastPac program. The vision tests and questionnaires are a part of
routine clinical care.
After enrollment, The investigators will obtain information about psychological factors by
administering the following questionnaires by phone on one occasion: Pittsburgh Sleep
Quality Index, Emotional Stability, Beck Depression Inventory, the Self-Motivation
Inventory, and the Life Experiences Survey. Questionnaires assessing health-related quality
of life (SF-36) and mental status (MMSE) will also be administered. The investigators will
use a phone version of the MMSE only for screening. Other variables that may be of
importance to the study will be assessed through a complete patient medical, ocular and
social history, including questions such as duration of visual impairment, occupation,
marital status, etc. The questionnaires are often used in research settings and sometimes in
clinical settings. Many patients appreciate the opportunity to provide feedback since these
areas are not always addressed as part of routine, clinical care. Focus group meetings,
facilitated by Dr. George and Lori Edwards, will help us begin to understand factors are
perceived to influence fluctuations in vision.
Subjects will participate in study procedures over the course of a 3 month period. This
includes an enrollment visit at our center with lab-based vision tests, and then
approximately 2 months PC-based vision testing.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |